Ristova Injection 500mg – 1 Vial x 10ml

Precision Treatment for Blood Cancers and Autoimmune Diseases

Ristova 500 mg Injection is an advanced monoclonal antibody therapy designed to target CD20-positive B-cells, which play a central role in the development of many blood cancers and immune-mediated disorders. As the first therapeutic monoclonal antibody developed to act on CD20 markers, Ristova represents a milestone in targeted immunotherapy.

This innovative treatment provides clinicians with a reliable option for managing complex hematological malignancies and autoimmune conditions through precise, immune-based intervention.

How Ristova Works

Ristova selectively binds to CD20 markers found on the surface of B-cells. These cells are responsible for driving diseases such as lymphoma, leukemia, and certain autoimmune disorders. Once attached, Ristova works through two complementary mechanisms: it directly damages the targeted B-cells and simultaneously activates the body’s immune system to destroy them.

This dual-action approach enhances therapeutic effectiveness while focusing treatment on disease-causing cells.

Comprehensive Oncology Applications

Ristova is approved for a wide range of blood cancers in adults, including previously untreated and relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Its versatility allows it to be used across different disease stages, including stable or non-progressing forms of lymphoma.

In pediatric patients aged six months and older, Ristova is approved for advanced-stage CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia. This broad approval highlights its importance in both adult and pediatric oncology care.

Autoimmune Disease Management

Beyond cancer treatment, Ristova also plays a vital role in managing autoimmune diseases. It is approved for adults with rheumatoid arthritis and pemphigus vulgaris, conditions where abnormal B-cell activity contributes to chronic inflammation and tissue damage.

Additionally, Ristova is indicated for both adults and children aged two years and older with granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. By reducing harmful B-cell activity, it helps control disease progression and immune dysfunction.

Flexible Treatment Options

Ristova 500 mg Injection may be administered alone or in combination with other medicines, depending on the patient’s diagnosis and treatment plan. This flexibility allows healthcare professionals to customize therapy based on disease severity, response, and clinical guidelines.

Medical Supervision and Administration

Ristova is administered as an injection under the supervision of trained healthcare professionals, typically in specialized medical facilities. Treatment schedules and dosage are determined by the physician based on patient-specific clinical needs.

Call to Action

Ristova 500 mg Injection offers a scientifically proven, targeted approach to treating CD20-positive blood cancers and autoimmune disorders. If you or a loved one requires advanced immunotherapy, consult a qualified healthcare professional to explore whether Ristova is the right treatment option. Choose precision-driven care backed by modern medical science.